Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705010 | 0.98 | CHRM2 (0.56) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL1244165 | 0.92 | — | — | |
| SCHEMBL28729222 | 0.82 | CHRM2 (0.56) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL3922973 | 0.79 | CHRM2 (0.58) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL9057404 | 0.79 | CHRM2 (0.58) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11727343 | 0.77 | CHRM2 (0.89) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11721410 | 0.77 | CHRM2 (0.89) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL3834112 | 0.76 | KMT2A (0.60) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11726121 | 0.74 | CHRM2 (0.93) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| SCHEMBL11725498 | 0.73 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6841682-B2 | Heterocycles useful in the treatment of benign prostatic hyperplasia | JANSEEN PHARMACEUTICA N.V. (BE) | 2005-01-11 | — | — | US | disclosed |
| EP-1273572-B1 | Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia | ORTHO MCNEIL PHARM INC (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1273572-A1 | Thiophene substituted piperazines useful in the treatment of benign prostatic hyperplasia | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020165219-A1 | Novel heterocycles useful in the treatment of benign prostatic hyperplasia | HUTCHINGS RICHARD H (US) | 2002-11-07 | — | — | US | disclosed |
| US-6384035-B1 | TREATING A DISEASE MEDIATED BY THE .ALPHA.-1.SUB.A ADRENERGIC RECEPTOR COMPRISING ADMINISTERING A COMPOUND | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-05-07 | — | — | US | disclosed |
| EP-1025085-A1 | HETEROCYCLES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND INTERMEDIATES THEREOF | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999019299-A1 | HETEROCYCLES USEFUL IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND INTERMEDIATES THEREOF | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165219-A1 | Novel heterocycles useful in the treatment of benign prostatic hyperplasia | ADRA1A, ADRB1, ADRA1D | CHRM2 574/4885CHRM5 754/4885CHRM1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.